Riamilovir sodium hydrate

Overview
Catalog #	bs-7015c-10mg-solid
Product Name	Riamilovir sodium hydrate
Specifications
Storage Buffer	Powder
Storage Condition	Store in dry, dark place at -20C for 1 year.
Target
Product Information	Molecular Weight: 310.2 Formula: C5 H8 N6 Na2 O5 S CAS Number: 928659-17-0 InChi Key: RPBLQPMOBSLKTG-UHFFFAOYSA-N InChi: InChI=1S/C5H4N6O3S.2Na.2H2O/c1-15-5-6-4-8-7-2(11(13)14)3(12)10(4)9-5;;;;/h1H3,(H,6,8,9);;;2*1H2 Smiles: O.O.[Na].[Na].CSC1NN2C(N=1)=NN=C(C2=O)[N+]([O-])=O \|^1:2,3\| Purity: 98.0 Solubility: Soluble in DMSO Appearance: Solid Power. Shelf Life: 1.0 years
Description	Riamilovir, also known as Triazavirin, is an antiviral drug candidate. Tiazavirin is a broad-spectrum antiviral drug developed in Russia. It has a novel triazolotriazine core, which represents a new structural class of non-nucleoside antiviral drugs. It was originally developed as a potential treatment for pandemic influenza strains such as H5N1, and most of the testing that has been done has focused on its anti-influenza activity. However triazavirin has also been found to have antiviral activity against a number of other viruses including Tick-borne encephalitis virus, and Forest-Spring Encephalitis virus, and is also being investigated for potential application against Lassa fever and Ebola virus disease. In February 2020, testing of triazavirin was started against SARS-CoV-2.